About Us

NextGen Immuno Therapeutics is a HealthTech company developing AiResolve, a Predictive Immune Intelligence and Precision Medicine Platform designed to transform complex clinical, molecular, and immune data into actionable insights for personalized patient care.

AiResolve integrates clinical and longitudinal patient data with multimodal and immune profiling, supported by explainable AI, to enable earlier risk prediction, personalized disease and treatment assessment, and longitudinal immune monitoring. AiResolve is secure, GDPR-compliant, and seamlessly integrates with existing hospital IT systems.

The company's initial clinical focus is Hematology and Cell Therapy, particularly stem cell/bone marrow transplantation, graft-versus-host disease (GVHD), and CAR-T therapy. From this focused entry point, AiResolve is designed to expand into oncology, autoimmune and chronic inflammatory diseases, and solid-organ transplantation, alongside applications in pharma precision medicine, including biomarker discovery, patient stratification, treatment-response prediction, and companion diagnostics.

Our Solution: AiResolve

Multimodal data Integration

Combines Multimodal data with clinical data to deliver high-resolution, actionable insights.

Early Detection

AiResolve Early Detection empowers clinicians to identify immune related diseases at the pre-symptomatic stage, enabling timely intervention and personalized treatment. This leads to significantly improved survival rates, reduced treatment time, and lower healthcare costs.

Biomarker Discovery

AiResolve’s biomarker discovery for cancer, autoimmune and Graft-versus-host disease (GVHD) uses multi-omics and explainable AI to detect early immune dysregulation—such as T cell activation, Treg imbalance, and APC dysfunction—after transplant. This enables early risk prediction, patient stratification, and timely interventions to improve outcomes and reduce complications.

Patient stratification

AiResolve uses multimodal data with clinical data and explainable AI to identify molecular fingerprints that distinguish high-risk vs. low-risk patients, responders vs. non-responders, or early vs. advanced disease stages.

Additional Treatment Discovery

AiResolve accelerates additional treatment discovery to reveal hidden therapeutic opportunities. The platform identifies drug repurposing candidates, discovers synergistic drug combinations, and provides insights into patient-specific therapy responses. By mapping immune dysfunction and tumor escape pathways, AiResolve not only uncovers new treatment options but also helps refine existing ones, enabling personalized, cost-effective, and faster-to-market solutions for cancer, autoimmune disorders, and transplant-related complications.

GDPR/MDR Compliant

Ensures data privacy, regulatory alignment, and seamless clinical integration across hospital systems.

How AiResolve Works

From Complex Patient Data to Actionable Clinical Insight

AiResolve combines clinical and longitudinal data with multimodal and immune profiling, then applies explainable AI to generate patient-specific insights for risk assessment, biomarker discovery, treatment-response evaluation, and longitudinal monitoring.

Patient & Biological Inputs

Clinical & longitudinal data
Genomic & transcriptomic profiling
Immune & cellular profiling
Proteomic & metabolomic data

AiResolve

Predictive Immune Intelligence & Precision Medicine Engine
Multimodal Integration Explainable AI Immune Intelligence Patient-specific Models

Clinical & Translational Outputs

Early risk prediction
Biomarker discovery
Patient stratification
Treatment & monitoring insights
01
CollectClinical and molecular data
02
ProfileGenerate multimodal immune profiles
03
IntegrateUnify biological and clinical signals
04
InterpretExplainable predictive intelligence
05
Act & MonitorPersonalized insights over time

Our Team

AiResolve is led by a world-class team of scientists, clinicians, and entrepreneurs with expertise in computational biology, immunology, clinical dermatology, and biotech strategy. Together, we bridge science and business to bring transformative diagnostics to patients worldwide.

Dr. Ram Vinay Pandey
Dr. Ram Vinay Pandey, PhD

Founder & CEO

Dr. Hanna Knaus, M.D., Ph.D.
Dr. Hanna Knaus, M.D., Ph.D.

Co-founder & Clinical Lead

Amit Kumar Chauhan
Amit Kumar Chauhan

Chief Strategy Officer (CSO), Austria, India

Dr. Lusia Unterluggauer
Dr. Lusia Unterluggauer

Clinical Scientist

Dr. Anand Kant Das, PhD
Dr. Anand Kant Das, PhD

Business Lead, Abu Dhabi, UAE

Prof. george
Prof. George Stary, MD, PhD

Co-founder & CSO

Jaishree Singh
Jaishree Singh

CIO & AI/ML Expert, Vienna

Dr. Rabindranath Paul, PhD
Dr. Rabindranath Paul, PhD

Scientific Lead, Abu Dhabi, UAE

Swathi dutt
Swathi Dutt

AI Strategist – Bioinformatics

Dr. Priyanka Dutta
Dr. Priyanka Dutta Passecker, MBA, PhD

Business Development Expert

Juraj Hunák, MSc (WU)
Juraj Hunák, MSc (WU)

Chief Financial Officer (CFO)

Laura Maria Gail
Laura Maria Gail

Immunologist

Nishant Kumar Verma
Nishant Kumar Verma

CTO & AI/ML Expert, Vienna

Advisory Board

From Vision to Validation—Strategic Guidance Backed by Decades of Success

Prof. Werner Rabitsch
Prof. Werner Rabitsch

Stem Cell Transplant Expert

Prof. Yenan Bryceson
Prof. Yenan Bryceson

Cancer Immunologist

Dr. André Rendeiro
Dr. André Rendeiro

Computational Biology/AI Expert

Prof. Robert Zeiser
Prof. Robert Zeiser

Hematologist, Oncologist

Prof. Hildegard Greinix
Prof. Hildegard Greinix

GVHD Expert

Dr. Andreas Weinhäusel
Dr. Andreas Weinhäusel

Molecular Diagnostics Expert

Martin Rudolf, BS IBA
Martin Rudolf, BS IBA

Business Development Advisor

Dr. Marc J. Brehme
Dr. Marc J. Brehme, MBA

Strategy & Fundraising Advisor

Florian Glatt-Wodzyński
Florian Glatt-Wodzyński

Business & Regulatory Advisor

Martin Rudolf, BS IBA
Gaurav Gandhi

Strategic Advisor, Austria

Dr. Constance Ciaudo Beyer, PhD
Dr. Constance Ciaudo Beyer, PhD

Senior Investment Advisor

Zurich, Switzerland

Our Strategic Partners

Collaborating with world-renowned institutions to advance precision medicine and transform healthcare.

Medical University of Vienna | Visit Website →

One of Europe's leading academic health centers, closely affiliated with Vienna General Hospital (AKH Wien) for access to highly specialized departments and digitalized clinical environments.

  • Practical validation of hospital IT integration
  • Standards-driven evolution of the MVP
  • Early clinical feedback to increase market readiness
Medical University of Graz | Visit Website →

A leading hub for biomedical research and digital health in Central Europe, integrated with LKH-Univ. Klinikum Graz for system-level testing and validation.

  • Access to structured clinical datasets
  • Real-world validation insights
  • Strengthened credibility with stakeholders
Karolinska Institutet, Stockholm | Visit Website →

A global pioneer in translational medicine and digital health innovation, bridging cutting-edge clinical research with large-scale deployment of AI and healthcare technologies.

  • Trusted medical data standards (e.g., SNOMED CT, FHIR)
  • Early validation in real-world clinical settings
  • International credibility and recognition
CeMM Research Centre | Visit Website →

CeMM is a leading European institute at the intersection of biomedicine, systems biology, and precision medicine — embedded within the clinical ecosystem of Vienna General Hospital (AKH).

Austrian Institute of Technology (AIT) | Visit Website →

Austria's premier applied research center for digital health and clinical decision support — supporting MDR/EU AI Act alignment, clinical algorithms, and real-world deployment.

Prognica Labs | Visit Website →

Accelerating drug discovery from molecule to medicine through autonomous AI agents and computational platforms.

  • 10× faster discovery via AI automation
  • Lower early-stage costs through in-silico evaluation
  • Reduced clinical risk using digital twin simulations
Mind & Matter | Visit Website →

NextGen Immuno Therapeutics and Mind & Matter have entered into a strategic collaboration to provide smart, AI-driven digital solutions across Europe and India.

Key Areas of Collaboration:

  • Government Healthcare Projects: Cancer screening, autoimmune disease management, chronic disease monitoring, stem cell transplantation support, population health analytics, and clinical decision support.
  • AI-Enabled Healthcare: Combining NextGen's immune intelligence and precision medicine technologies with Mind & Matter's AI and small language model development capabilities.
  • Digital Health Solutions: Healthcare dashboards, mobile applications, hospital AI platforms, patient engagement, analytics, and secure healthcare data systems.
  • Innovation & Research: Immuno Intelligence and Precision Medicine Innovation Centre.
  • Education & Capacity Building: Supporting knowledge development in AI in Healthcare, Digital Health, Precision Medicine, Preventive Healthcare, and Healthcare Data Analytics.

Publications

Our team has published extensively in top-tier journals such as Science, Immunity, and Journal of Experimental Medicine, advancing the fields of computational immunology, Oncology, GVHD research, and precision diagnostics.

  1. Strobl J, Gail LM, Krecu L, Madad S, Kleissl L, Unterluggauer L, Redl A, Brazdilova K, Saluzzo S, Wohlfarth P, Knaus HA, Mitterbauer M, Rabitsch W, Haniffa M, Stary G. Diverse macrophage populations contribute to distinct manifestations of human cutaneous graft-versus-host disease. Br J Dermatol. 2024 Feb 16;190(3):402-414.
    DOI: 10.1093/bjd/ljad402 | PMID: 38010706 | PMCID: PMC10873647.

  2. Pandey RV, Strobl J, Redl A, Unterluggauer L, Gail L, Kleissl L, Müller S, Atzmüller D, Fife-Gernedl V, Krausgruber T, Knaus H, Mitterbauer M, Wohlfarth P, Rabitsch W, Bock C, Stary G. Epigenetic regulation of T cell lineages in skin and blood following hematopoietic stem cell transplantation. Clin Immunol. 2023 Mar;248:109245.
    DOI: 10.1016/j.clim.2023.109245 | PMID: 36702179.

  3. Strobl J, Gail LM, Kleissl L, Pandey RV, Smejkal V, Huber J, Puxkandl V, Unterluggauer L, Dingelmaier-Hovorka R, Atzmüller D, Krausgruber T, Bock C, Wohlfarth P, Rabitsch W, Stary G. Human resident memory T cells exit the skin and mediate systemic Th2-driven inflammation. J Exp Med. 2021 Nov 1;218(11):e20210417.
    DOI: 10.1084/jem.20210417 | PMID: 34643646 | PMCID: PMC8563284.

  4. Strobl J, Pandey RV, Krausgruber T, Bayer N, Kleissl L, Reininger B, Vieyra-Garcia P, Wolf P, Jentus MM, Mitterbauer M, Wohlfarth P, Rabitsch W, Stingl G, Bock C, Stary G. Long-term skin-resident memory T cells proliferate in situ and are involved in human graft-versus-host disease. Sci Transl Med. 2020 Nov 18;12(570):eabb7028.
    DOI: 10.1126/scitranslmed.abb7028 | PMID: 33208504 | PMCID: PMC7615006.

  5. Strobl J, Pandey RV, Krausgruber T, Kleissl L, Reininger B, Herac M, Bayer N, Krall C, Wohlfarth P, Mitterbauer M, Kalhs P, Rabitsch W, Bock C, Hopfinger G, Stary G. Anti-Apoptotic Molecule BCL2 Is a Therapeutic Target in Steroid-Refractory Graft-Versus-Host Disease. J Invest Dermatol. 2020 Nov;140(11):2188-2198.
    DOI: 10.1016/j.jid.2020.02.029 | PMID: 32247860.

  6. Lim CX, Redl A, Kleissl L, Pandey RV, Mayerhofer C, El Jammal T, Mazic M, Gonzales K, Sukhbaatar N, Krausgruber T, Bock C, Hengstschläger M, Calender A, Pacheco Y, Stary G, Weichhart T. Aberrant Lipid Metabolism in Macrophages Is Associated with Granuloma Formation in Sarcoidosis. Am J Respir Crit Care Med. 2024 May 1;209(9):1152-1164.
    DOI: 10.1164/rccm.202307-1273OC | PMID: 38353578 | PMCID: PMC7617514.

  7. Zitti B, Hoffer E, Zheng W, Pandey RV, Schlums H, Perinetti Casoni G, Fusi I, Nguyen L, Kärner J, Kokkinou E, Carrasco A, Gahm J, Ehrström M, Happaniemi S, Keita ÅV, Hedin CRH, Mjösberg J, Eidsmo L, Bryceson YT. Human skin-resident CD8+ T cells require RUNX2 and RUNX3 for induction of cytotoxicity and expression of the integrin CD49a. Immunity. 2023 Jun 13;56(6):1285-1302.e7.
    DOI: 10.1016/j.immuni.2023.05.003 | PMID: 37269830.

  8. Kokkinou E, Soini T, Pandey RV, van Acker A, Theorell J, Czarnewski P, Kvedaraite E, Vandamme N, Lourda M, Sorini C, Weigel W, Carrasco A, Tibbitt CA, Schlums H, Lindforss U, Nordenvall C, Ljunggren M, Ideström M, Svensson M, Henter JI, Villablanca EJ, Bryceson YT, Rolandsdotter H, Mjösberg J. The single-cell transcriptional landscape of innate and adaptive lymphocytes in pediatric-onset colitis. Cell Rep Med. 2023 May 16;4(5):101038.
    DOI: 10.1016/j.xcrm.2023.101038 | PMID: 37160121 | PMCID: PMC10213874.

  9. Stary V, Pandey RV, List J, Kleissl L, Deckert F, Kabiljo J, Laengle J, Gerakopoulos V, Oehler R, Watzke L, Farlik M, Lukowski SW, Vogt AB, Stary G, Stockinger H, Bergmann M, Pilat N. Dysfunctional tumor-infiltrating Vδ1+ T lymphocytes in microsatellite-stable colorectal cancer. Nat Commun. 2024 Aug 13;15(1):6949.
    DOI: 10.1038/s41467-024-51025-1 | PMID: 39138181 | PMCID: PMC11322529.

Contact Us

Dr. Ram Vinay Pandey, PhD, Founder & CEO
NextGen Immuno Therapeutics
Nippongasse 8, 1220, Vienna, Austria
office@nextgenimmuno.com
+43 650 7276982
https://www.linkedin.com/in/ram-vinay-pandey1